Brokerages Set AngioDynamics, Inc. (NASDAQ:ANGO) Target Price at $19.33

AngioDynamics, Inc. (NASDAQ:ANGO) has been given an average rating of “Moderate Buy” by the five brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $19.3333.

ANGO has been the subject of a number of recent analyst reports. Zacks Research raised shares of AngioDynamics from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, January 21st. Finally, Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Sunday, December 21st.

AngioDynamics Stock Up 4.6%

Shares of ANGO opened at $11.37 on Friday. The business’s 50 day moving average is $10.83 and its two-hundred day moving average is $11.55. AngioDynamics has a 52-week low of $8.36 and a 52-week high of $13.99. The firm has a market cap of $468.67 million, a price-to-earnings ratio of -16.97 and a beta of 0.48.

Hedge Funds Weigh In On AngioDynamics

A number of hedge funds have recently bought and sold shares of the company. State of Alaska Department of Revenue bought a new stake in AngioDynamics in the third quarter valued at about $25,000. Farther Finance Advisors LLC lifted its holdings in AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 1,199 shares during the last quarter. Washington Trust Advisors Inc. bought a new position in AngioDynamics during the 3rd quarter worth approximately $27,000. Kemnay Advisory Services Inc. acquired a new position in shares of AngioDynamics in the 4th quarter worth approximately $27,000. Finally, State of Wyoming bought a new stake in shares of AngioDynamics in the 2nd quarter valued at approximately $31,000. 89.43% of the stock is currently owned by institutional investors and hedge funds.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.